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Abstract
Background: Neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF), have shown great promise for
protection and restoration of damaged or dying dopamine neurons in animal models and in some Parkinson’s disease (PD)
clinical trials. However, the delivery of neurotrophic factors to the brain is difficult due to their large size and poor bio-distribution.
In addition, developing more efficacious trophic factors is hampered by the difficulty of synthesis and structural modification.
Small molecules with neurotrophic actions that are easy to synthesize and modify to improve bioavailability are needed.
Methods and Findings: Here we present the neurobiological actions of dopamine neuron stimulating peptide-11 (DNSP-
11), an 11-mer peptide from the proGDNF domain. In vitro, DNSP-11 supports the survival of fetal mesencephalic neurons,
increasing both the number of surviving cells and neuritic outgrowth. In MN9D cells, DNSP-11 protects against
dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA)-induced cell death, significantly decreasing TUNEL-positive cells
and levels of caspase-3 activity. In vivo, a single injection of DNSP-11 into the normal adult rat substantia nigra is taken up
rapidly into neurons and increases resting levels of dopamine and its metabolites for up to 28 days. Of particular note,
DNSP-11 significantly improves apomorphine-induced rotational behavior, and increases dopamine and dopamine
metabolite tissue levels in the substantia nigra in a rat model of PD. Unlike GDNF, DNSP-11 was found to block
staurosporine- and gramicidin-induced cytotoxicity in nutrient-deprived dopaminergic B65 cells, and its neuroprotective
effects included preventing the release of cytochrome c from mitochondria.
Conclusions: Collectively, these data support that DNSP-11 exhibits potent neurotrophic actions analogous to GDNF,
making it a viable candidate for a PD therapeutic. However, it likely signals through pathways that do not directly involve
the GFRa1 receptor.
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Introduction
A hallmark of Parkinson’s disease (PD) is the degeneration of
dopamine neurons in the pars compacta of the substantia nigra
[1]. Glial cell line-derived neurotrophic factor (GDNF), has been
extensively shown to be a promising PD therapeutic that promotes
the survival of dopamine neurons, protects against neurotoxin-
induced injury, and has powerful restorative effects for damaged
or dying dopamine neurons [2–8]. However, the widespread
clinical application of GDNF has been hindered, in part, as a
consequence of its heparin-binding domains and large molecular
size limiting brain diffusion [6]. Thus, finding a small molecule
with potent neurotrophic effects has important implications in the
treatment of PD.
The emergence of naturally occurring, physiologically functional
propeptides from the neurotrophic factor family provides a wealth of
untapped sequences for exploration and pharmacological evaluation
[9]. Neurotrophic factor propeptide sequences have historically been
thought to have very little - if any - function, except to promote
protein folding and regulation of secretion [10,11]. However, the
prodomains of nerve growth factor (NGF) and brain derived
neurotrophic factor (BDNF) have been determined to bind to the
pro-apoptotic receptor, sortilin, and promote cell-death by recruiting
the mature p75NTR receptor when the dibasic furin cleavage site
has been mutated (removed) between the prodomain and the
mature growth factor [12–14]. In addition, studies have shown that
the isolated prosequence of NGF can be used to block the induction
of apoptosis, by likely preventing the proapoptotic ternary complex
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(sortilin-p75NTR-proNGF) formation [13]. While these findings are
quite surprising, they strongly suggest that the highly conserved
prosequences of other related neurotrophic factors contain novel,
physiologically relevant functions.
Like all neurotrophic factors, GDNF is endogenously produced
as a proprotein following signal peptidase cleavage of the N-
terminal 19 amino acid residue presequence [2]. Examination of
the human GDNF prosequence predicts internal dibasic endo-
peptidase sites that would yield an 11-mer amidated peptide
named Dopamine Neuron Stimulating Peptide-11 (DNSP-11),
upon proteolytic processing (Figure 1A) [15]. Independently, the
rat homolog of DNSP-11, named brain excitatory peptide (BEP),
was found to be a functional neuropeptide, exhibiting an increase
in synaptic excitability [15]. Here we present that DNSP-11
exhibits potent neurotrophic actions analogous to mature GDNF,
making it a viable candidate for a PD therapeutic, but it likely
signals through pathways that do not directly involve the GFRa1
receptor. These data strongly support that the pro-peptides of
GDNF, and other neurotrophic factors, may have novel, long-
overlooked physiological and potentially therapeutic functions.
Methods
Ethics Statement
All animal procedures were approved by our Institutional
Animal Care and Use Committee following AAALACI guidelines.
Materials
Unless otherwise stated, all cell reagents and assays were
purchased from Invitrogen. All other materials and chemicals are
hGDNF     PPEAPAEDRSL
rGDNF    LLEAPAEDHSL
mGDNF    LLEAPAEDHSL  
Figure 1. Sequence origin and homology of DNSP-11. (A) DNSP-11 (filled) is an 11 amino acid sequence present in the proprotein region of the
211 amino acid human pre-proGDNF sequence. After cleavage of the pre-signal sequence (gray), DNSP-11 is predicted to be cleaved from the
proprotein at flanking dibasic cleavage sites by endopeptidases. Further predicted processing yields the C-terminal amidated peptide. The N-terminal
(striped) and C-terminal (checkered) proprotein fragments and mature GDNF (open) protein are shown. The sequence figure is not drawn to scale to
highlight the processing of DNSP-11. (B) DNSP-11 shows high sequence homology to the rat and mouse proGDNF sequences suggesting a conserved
function. (C) In vivo expression of the DNSP-11 sequence in the substantia nigra of the ventral mesencephalon from rat pups at PN10. Rows indicate
the type of stain: the top panel is DNSP-11 (green); the middle panel is a dopaminergic neuron marker, tyrosine hydroxylase (TH+, red); the bottom
panel represents a merged image of the previous stains (yellow). The bottom panel demonstrates co-localization of DNSP-11 sequence within
dopaminergic cell bodies at PN10. The scale bar represents 30 mm.
doi:10.1371/journal.pone.0009752.g001
GDNF Propeptide DNSP-11
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reagent grade. B65 cells were obtained from ECACC. The
polyclonal rabbit anti-hDNSP-11 antibody was produced by
Alpha Diagnostic (San Antonio, Texas).
DNSP-11 and Biotinylated DNSP-11
DNSP-11 (sequence: PPEAPAEDRSL-amide) and biotinylated
DNSP-11 (bDNSP-11; sequence: biotin-PPEAPAEDRSL-amide)
were synthesized and RP-HPLC purified to .98% by AC Scientific
(Duluth, GA) and the W.M. Keck Foundation Biotechnology
Resource Laboratory at Yale University. Peptides were characterized
for purity and correct sequence by MALDI-TOF LC-MS and
Edman degradation. DNSP-11 was determined to be stable, in vitro, at
a variety of experimentally relevant concentrations and temperatures,
including 37uC in sterile pH 5 citrate buffer for 31 days.
Tissue preparation for DNSP-11 Staining in Substantia
Nigra at Postnatal Day 10 (PN10)
Tissue was prepared from Sprague Dawley (SD) pups. Brains
were rinsed in Dulbecco’s Phosphate Buffered Saline (DPBS,
Gibco), and submerged in 4% paraformaldehyde pH 7.4 for
48 hours. Following submersion in 30% sucrose, brains were
sectioned coronally (40 mm) and stored in cryoprotectant solution
at 270uC until processed for immunohistochemistry.
DNSP-11 treatment of Mesencephalic Cells
Timed pregnant SD rats (Harlan) were used to obtain the ventral
mesencephalon from E14 fetuses. The dissected tissue was collected
in cold NeurobasalTM medium and rinsed twice with cold PBS. The
cells were chemically (TrypLEH) and mechanically dissociated to
yield a single cell suspension. The solution was centrifuged at 169 g
for 6 minutes and the pellet re-suspended in Dulbecco’s Modified
Eagle Medium (DMEM). Cells were plated in a 25 mL micro-island
at a density of 4000 cells/ mL on poly-D-lysine coated 24-well plates
(Sigma). Following adherence, cells were supplemented with warm
NeurobasalTM media containing 2 mM glutamine and 100 units of
penicillin/streptomycin. Neurotrophic compounds were added at
each media addition, including initial plating and DIV 2. Peptides
(0.03 ng to 10 ng/mL) were added to a 24-well plate following media
supplementation.
MN9D and B65 Cell Cultures
MN9D [16] and B65 [17] cells were cultured in DMEM
supplemented with 10% Fetal Bovine Serum (FBS, Hyclone),
50 U/mL penicillin and streptomycin. For experiments, the cells
were plated on 24-well poly-D-lysine in DMEM with 1% (v/v)
penicillin-streptomycin. The cells were grown at 37uC in 5% CO2.
Caspase-3 Activity Assay in MN9D Cells
MN9D cells were plated to 100,000 cells/well. Cell cultures were
exposed to DNSP-11 (1 ng/mL) or buffer for 1 hour prior to 15 min
100 mM 6-OHDA exposure. Caspase-3 activity was monitored after
3 hours by fluorescence (lex/lem 496/520 nm) using the Enz Chek
Caspase-3 kit. Protein levels of lysed cells were measured by BCA
assay (BioRad) and normalized for every experiment. Data are
expressed as % control and were repeated a minimum of 3 times.
Terminal dUTP Nick-End Labeling (TUNEL) Assay in MN9D
Cells
After treatment with DNSP-11, MN9D cells were fixed and
labeled to assess degenerative nuclear changes as indicated by the
extent of high-molecular weight DNA strand breaks. DNA
fragmentation was detected by using streptavidin-horseradish
peroxidise conjugate followed by the substrate diaminobenzidine
(DAB) generating a colored precipitate. Ratios between apoptotic
and total cells were determined (4 random fields/well; 4 wells/
group). Experiments were repeated 3 times.
LIVE/DEADH Calcein AM/ Ethidium homodimer (EthD-1)
Assay
B65 cells were cultured in 96-well plates for 24 h and then
incubated with 2 mM calcein AM and 4 mM EthD-1 in PBS, at
RT for 60 min (LIVE/DEADH Viability/Cytotoxicity Assay Kit).
The hydrolysis of calcein AM in the cytoplasm of live cells was
monitored by fluorescence (lex/lem 485 nm/530 nm). EthD-1
binding to nucleic acids in damaged cells was monitored by
fluorescence (lex/lem 530 nm/645 nm). Background fluorescence
readings (cell-free control) were subtracted from all values prior to
calculation of results. The data were normalized to the
fluorescence in vehicle-treated cells and expressed as percent of
control 6S.E.M. of three to four independent experiments.
Cytochrome C Immunostaining
B65 cells were plated on coverslips in 24-well plate. Cells were
incubated for 30 min with MitotrackerH Red 0.1 mg/ml to stain
mitochondria with red fluorescence. After 30 min the medium was
replaced with DMEM medium (no FBS) and treated with
staurosporine (1 mM), DNSP-11 (10 ng/ml) and GDNF (1 ng/ml)
for 6 h. Each experiment was performed in triplicate wells. The cells
were fixed in 4% paraformaldehyde, permeabilized with 0.1% triton-
x100, and immunostained withmonoclonal antisera to cytochrome C
at 1:1000 dilution. Alexa-488 conjugated goat anti-mouse IgG (1:500)
was used as a secondary antiserum. The coverslips were mounted
onto slides with mounting media containing DAPI (VECTOR) to
stain the nuclei with blue fluorescence.
Double Fluorescent Immunostaining of DNSP-11
Floating sections were pretreated with 0.2% H2O2 in potassium
phosphate buffered saline (KPBS) for 10 minutes and blocked with
4% normal goat serum in KPBS for 1 hour. Then, sections were
incubated overnight with both rabbit anti-hDNSP-11 polyclonal
antibody (1:2000, Alpha Diagnostic) and mouse anti-TH antibody
(1:1000, Chemicon) in KPBS at 4uC. After washing with KPBS,
the sections were incubated with Alexa-488 conjugated goat anti-
rabbit IgG (1:500, Molecular Probes) and Alexa-568 conjugated
goat anti-mouse IgG (1:500, Molecular Probes) for 3 hours. The
sections were washed extensively and visualized with a Nikon
fluorescence microscope.
Animals and Surgical Procedures for Normal and 6-
OHDA-Lesioned Rats
Fischer 344 rats were used for all experiments and maintained
under a 12 hour light/dark cycle with food and water provided ad
libitum. All animal procedures were approved by our Institutional
Animal Care and Use Committee following AAALACI guidelines.
Infusion Delivery of DNSP-11 or Vehicle
Isoflurane anesthetized (1.5–2.5%) Fischer 344 rats received
5 ml of 6 mg/mL DNSP-11 solution or citrate buffer vehicle
solution in a blinded manner. Treatment was delivered to the
nigral cell bodies using the same stereotaxic coordinates and
protocol for solution delivery as in studies of GDNF [16].
Reverse Microdialysis
Reverse in vivo microdialysis was accomplished using previously
published methods and brain coordinates [18]. CMA 11
GDNF Propeptide DNSP-11
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microdialysis probes with a 4.0 mm membrane length and 6 kDa
molecular weight cut-off were placed within the rat striatum.
Unilateral 6-OHDA Lesions
The 6-OHDA solution was delivered to two injection sites along
the medial forebrain bundle (MFB) using a previously published
protocol [19]. Five weeks after the unilateral 6-OHDA MFB lesion
procedure, animals were grouped based on apomorphine (0.05 mg/
kg, s.c.)-induced rotational behaviour: animals with .300 rotations
per 60 minutes were selected. Lesioned animals received 5 mL of
either a 20 mg/mLDNSP-11 solution or citrate buffer vehicle solution
in a manner similar to infusion delivery in normal animals.
Neurochemical Content of Tissue
Lesioned animals were euthanized 5 weeks after DNSP-11 or
vehicle infusion. The brains were sliced into 1 mm thick sections.
Tissue punches were taken from the striatum and the substantia
nigra and they were weighed, quick frozen and stored at -70uC
until they were assayed by high performance liquid chromatog-
raphy with electrochemical detection [20].
Apomorphine–induced Rotational Behavior Testing
Lesion severity was assessed prior to DNSP-11 treatment using
apomorphine (0.05 mg/kg, s.c.)- induced rotational behavior.
Beginning one week after DNSP-11 treatment, apomorphine-
induced rotational behavior was monitored weekly for four weeks
[7,21].
DNSP-11 Pull-down Assay with Rat Substantia Nigra
Homogenate
Fischer 344 rat substantia nigra was homogenized in homog-
enization buffer (modified from [22] with 20 mM HEPES,
pH 7.4) and cytosolic fraction (supernatant) collected after 30
minutes at 100,000 g. 50 mg of bDNSP-11 was incubated with
fraction for 15 minutes on ice. Sample was added to streptavidin
magnetic beads (New England Biolabs), pelleted, and washed four
times in homogenization buffer. Bound proteins were eluted by
Solubilization/Rehydration Solution (7 M Urea, 2 M Thiourea,
50 mM DTT, 4% CHAPS, 1% NP-40, 0.2% Carrier ampholytes,
0.0002% Bromophenol blue), and analyzed by 2D-PAGE
(BioRad) and later identified by MALDI-TOF MS/MS. MS data
were compared to the Uniprot [23] database utilizing the
ParagonTM algorithm [24] in ProteinPilot Version 2.0 (Applied
Bioscience).
Results
DNSP-11 is an 11-mer peptide that we and others have
predicted to be an endopeptidase cleavage product from the
human GDNF prosequence (Figure 1A) [15]. Homologous
sequences have also been predicted from the rat and mouse
GDNF prosequence (Figure 1B) [15]. Endogenous immuno-
staining for DNSP-11 in the mesencephalon of Sprague Dawley
(SD) rats indicates that the sequence is uniformly distributed
throughout the perikaryal cytoplasm of tyrosine hydroxylase
positive (TH+) labeled neurons of the substantia nigra at postnatal
day 10 (PN10; Figure 1C) analogous to GDNF, while
immunostaining in the striatum is at background levels (data not
included). In addition, the DNSP-11 sequence has also been
detected in the olfactory bulb, granule cells in the hippocampus,
granule cells in the cerebellum and the locus coeruleus (data not
included). The observed punctate (granular) immunofluorescence
comes from labeled neurites emanating from labeled cell bodies.
The source of the DNSP-11 seen in nigral dopamine neurons is
not known at this time. Immunostaining with this polyclonal
Figure 2. Uptake of DNSP-11 into the rat substantia nigra 30 minutes after a single injection. The fluorescent immunostaining for DNSP-
11 (A), TH (B) and the two photomicrographs merged (C) show that DNSP-11 is taken up by neurons in both the substantia nigra, pars reticulata (SNr)
and substantia nigra, pars compacta (SNc). TH-positive dopamine neurons (B) populate the SNc and the ventral tegmental area (VTA). Figures D-F are
higher power micrographs from the SNc. Immunostaining (D) revealed uptake of DNSP-11 into the perikaryon (large arrow), nucleus (small arrow),
and neurites of TH+ cells (E), which appear yellow in the merged imaged (F), including the two cells denoted by arrowheads. The injection site is
indicated (star). Scale bar = 200 mm in A-C; 15 mm in D-F.
doi:10.1371/journal.pone.0009752.g002
GDNF Propeptide DNSP-11
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antibody does not distinguish between the 11-mer peptide or
proGDNF form of the DNSP-11 sequence.
To determine if DNSP-11 is actively taken up into dopamine-
containing neurons in vivo, a single administration of 30 mg of
DNSP-11 was delivered into the right rat substantia nigra.
Animals were euthanized at 0.5, 1.5, 4, 24 and 48 hrs after
injection to visualize distribution of DNSP-11 using a polyclonal
antibody raised against DNSP-11. As seen in Figure 2, DNSP-11
antibodies labeled the cytosol and neurites of neurons in the area
of the substantia nigra within 30 minutes after injection. In
addition, staining for TH+ and DNSP-11 showed overlap in the
pars compacta of the substantia nigra and some DNSP-11
labelling in the pars reticulata - supporting potential uptake into
c-aminobutyric acid-ergic (GABAergic) neurons. The pars retic-
ulata serves as a major efferent pathway from the basal ganglia to
the thalamus and brainstem. Thus drugs that affect neurons in the
pars reticulata could have significant therapeutic value. Immuno-
histochemical staining for DNSP-11 diminishes 3 hrs after
injection and was absent at 24 hrs and beyond (data not shown),
supporting that there is a rapid uptake of DNSP-11 into neurons.
We studied the neurotrophic effects of DNSP-11 by comparing
it to the well-known effects of GDNF on the maintenance of
Figure 3. Neurotrophic effects of DNSP-11 and GDNF in Primary Dopaminergic Neurons. (A) E14 rat embryo primary dopaminergic
neurons from the ventral mesencephalon were grown for 5 days in vitro and neurotrophic molecules were added at each media change, including
initial plating and day 2. GDNF (open bars) and DNSP-11 (blue bars) were added at various concentrations (0.03, 0.1, 1.0 and 10 ng/ml; 10 mM citrate
buffer +150 mM NaCl, pH 5) and were seen to significantly increase TH+ neuron counts (+ SE; one-way ANOVA with Newman-Keuls post hoc analysis,
*p,0.05 and **p,0.01) (B) Photographs of treated E14 primary dopaminergic neurons demonstrating that both GDNF and DNSP-11 treated cells
(0.1 ng/ml) displayed enhanced cell survival, neurite length, and total number of branches.
doi:10.1371/journal.pone.0009752.g003
GDNF Propeptide DNSP-11
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primary mesencephalic cell cultures from E14 SD rat embryos.
DNSP-11 significantly increased cell survival 75% over citrate
buffer control, as indicated by immunocytochemical staining of
TH+ neurons 5 days in vitro (Figure 3A). As previously observed,
GDNF produces a decrease in TH+ staining at higher dosages
[25,26]. However, DNSP-11’s effects remained constant between
0.03 to 10 ng/mL (Figure 3A). Additional dosing studies are
necessary to determine the upper and lower limits of DNSP-11 in
primary cell culture. Furthermore, DNSP-11 significantly en-
hanced morphological changes (Figure 3B) consistent with a
neurotrophic molecule including: neurite length, total number of
branches, and increased total number of TH+ cells (Table 1).
These effects were similar to those observed for GDNF [2] in these
cells, including an increase in the size of TH+ neurons, which was
not observed for DNSP-11 (Table 1).
Prior in vivo studies with GDNF have shown robust effects on
both potassium- and amphetamine-evoked dopamine release 28
days after a single injection into the rat substantia nigra [27]
Table 1. E14 Primary mesencephalic neuron survival and morphological data following treatment with GDNF and DNSP-11.
GDNF DNSP-11
Control (n) 0.1 ng/mL (n) Control (n) 0.1 ng/mL (n)
Cell survival 100615 (8) * 158612 (8) 100616 (7) *161617 (7)
Combined neurite length (mm) 242612 (135) ** 310616 (106) 222611 (139) ** 306623 (59)
Soma size (mm2) 17164 (135) 17764 (106) 16863 (139) 16565 (59)
Average branches per neuron 3.860.2 (135) ** 4.760.2 (106) 3.160.2 (139) ** 4.460.3 (59)
Cell survival and morphological parameters were quantified for control (citrate buffer) and experimental (0.1 ng/ml GDNF or 0.1 ng/ml DNSP-11) conditions. For
morphology, five fields per well (minimum of 15 cells/field; 3–4 independent experiments) were photographed at 20x magnification and quantified using a Bioquant
Image Analysis System. DNSP-11 increased cell survival and morphological parameters comparable to GDNF, including combined neurite length and total branches.
Soma size was not increased by the addition of DNSP-11. A one-way ANOVA was used to test for significance among groups, followed by a Newman-Keuls post hoc
analysis. Significance between control and experimental conditions was determined at *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0009752.t001
Figure 4. Neurotrophic effects of DNSP-11 in vivo. (A) 28 days after DNSP-11 (30 mg) or citrate buffer vehicle was delivered to the nigral cell
bodies, neurochemical studies were carried out in the ipsilateral striatum with in vivo microdialysis and levels of DA and its metabolites, DOPAC and
HVA were determined. The DNSP-11 treatment group showed significantly higher basal neurochemical concentrations of DA, DOPAC and HVA. Basal
DA increased from 26.062.7 nM in the vehicle treatment group to 45.867.7 nM in the DNSP-11 treatment group (t(31) = 2.255, p = 0.0314). Basal
concentrations of DOPAC increased from 33556338 nM in the vehicle group to 65446836 nM in the DNSP-11 group (t(31) = 3.293, p = 0.0025), and
HVA, increased from 24196251 nM with vehicle treatment to 45166502 nM with DNSP-11 treatment (t(30) = 3.588, p = 0.0012). All data were analyzed
using a two-tailed unpaired t-test *p,0.05. (B) Apomorphine (0.05 mg/kg) induced rotational behavior was assessed prior to infusion treatment (Pre)
and once weekly for 4 weeks after DNSP-11 (100 mg) or vehicle treatment. Drug-induced rotational behavior is expressed as a percentage of vehicle
treatment and showed a significant decrease in rotational behavior beginning one week after DNSP-11 treatment that lasted for all 4 weeks post
DNSP-11. The data were analyzed using a one-way ANOVA for repeated measures (F(4,39) = 4.807, p = 0.0005) with Bonferroni’s multiple comparison
test *p,0.05, **p,0.01, ***p,0.001. (C) DNSP-11 treatment significantly increased levels of DA, (74%) and DOPAC (132%) in the substantia nigra of
unilateral 6-OHDA-lesioned rats. DA content was determined to be 34.766.4 ng/g in the vehicle treatment group and 59.167.3 ng/g in the DNSP-11
treatment group (t(13) = 2.521, p = 0.0265). DOPAC tissue content was determined to be 7.1061.40 ng/g in the vehicle treatment group and
16.4864.01 ng/g (t(13) = 2.33, p = 0.0364) in the DNSP-11 treatment group. All data were analyzed using a two-tailed unpaired t-test, * p,0.05.
doi:10.1371/journal.pone.0009752.g004
GDNF Propeptide DNSP-11
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indicating the functional effects of this trophic factor on dopamine
signaling in the normal rat striatum. In our studies, 30 mg of
DNSP-11 was injected into the right substantia nigra of normal
young male Fischer 344 rats. Twenty-eight days after injection, in
vivo microdialysis was performed in these animals to investigate
dopamine neurochemistry in the ipsilateral striatum. Resting levels
of dopamine, and the dopamine metabolites 3,4-dihydroxyphe-
nylacetic acid (DOPAC) and homovanillic acid (HVA), were
Figure 5. DNSP-11 functions differently than GDNF. Both DNSP-11 and GDNF protect against 6-OHDA toxicity as demonstrated by reductions
in TUNEL staining at 24 h (A) and caspase-3 (B) activity at 3 h after 6-OHDA exposure. MN9D dopaminergic cells were incubated for 1 hour with either
citrate buffer (control), 1 ng/mL of DNSP-11 or GDNF prior to 100 mM 6-OHDA exposure for 15 min. Data are + SD, one-way ANOVA with Tukey’s post
hoc analysis, *p,0.05, **p,0.01, ***p,0.001 vs. control; #p,0.05, ##p,0.01, ###p,0.001 vs. 6-OHDA. (C) DNSP-11 reduces staurosporine-
induced cytotoxicity (1 mM) by ,125% as measured by LIVE/DEADH assay in dopaminergic B65 cells, whereas GDNF offers no protection at 20 hours
after treatment. Control was citrate buffer alone; GDNF and DNSP-11 were added at 1 ng/mL. STS-staurosporine. (D) Similarly, DNSP-11 reduces
gramicidin-induced cytotoxicity (1 mM) by ,60%, whereas GDNF offers no protection at 20 hours after treatment. One-way ANOVA used to test for
significance among groups, followed by Tukey’s post hoc analysis (*p,0.05, **p,0.01, ***p,0.001 vs control; #p,0.05, ##p,0.01, ###p,0.001
vs toxin). Gram-gramicidin.
doi:10.1371/journal.pone.0009752.g005
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significantly increased by over 100% in the DNSP-11 treated rats
as compared to controls (Figure 4A). These data support longer
term effects of DNSP-11 on dopamine neuron function, and are
analogous to prior results involving GDNF administration in rats
and nonhuman primates [16,28].
The in vitro studies and in vivo measures of the neurotrophic
effects of DNSP-11 led us to investigate the potential neuror-
estorative properties of DNSP-11 to damaged dopamine neurons
in a unilateral rat model of PD. Fischer 344 rats received dual-site
unilateral injections of 6-OHDA to produce extensive destruction
of the ascending dopaminergic system that resulted in a greater
than 99% depletion of striatal dopamine content and a greater
than 97% depletion of nigral dopamine content ipsilateral to the
site of the 6-OHDA injections. Rats were tested 3–4 weeks after
the injection of 6-OHDA using low-dose (0.05 mg/kg, i.p.)
apomorphine to induce rotational behavior. In rats that rotated
greater than 300 turns/ 60 minutes, 100 mg of DNSP-11 was
injected into the substantia nigra ipsilateral to the 6-OHDA
injections. DNSP-11 produced a significant ,50% decrease in
apomorphine-induced rotational behavior that was significant 1
week after administration and this effect was maintained for at
least 4 weeks after DNSP-11 (Figure 4B). At 5 weeks, tissue
samples of the substantia nigra and striatum from each rat were
analyzed by high performance liquid chromatography coupled
with electrochemical detection (HPLC-EC). A single injection of
DNSP-11 was found to significantly increase levels of dopamine
and the dopamine metabolite, DOPAC, by ,100% in the
substantia nigra, supporting that DNSP-11 has a powerful
neurotrophic-like restorative effect on dopamine neurons in this
animal model of late stage PD (Figure 4C). As observed with a
single injection of GDNF [4], no significant changes in dopamine
or its metabolites, DOPAC and HVA, were observed in the
lesioned striatum (data not included).
To evaluate DNSP-11’s cellular neuroprotective properties,
DNSP-11 was compared to GDNF in its protection against 6-
OHDA-induced toxicity in the MN9D dopaminergic cell line. As
seen in Figures 5A & 5B, 100 mM 6-OHDA significantly
increased TUNEL staining and caspase-3 activity in MN9D cells.
Pretreatment with DNSP-11 or GDNF produced a significant
reduction in the percent of TUNEL positive cells and caspase-3
activity. To gain insight into DNSP-11’s cellular mechanism, a
DNSP-11 pull-down assay with cytosolic homogenate from
isolated substantia nigra of normal young Fischer 344 rats was
performed (Figure S1). Of the 16 proteins that were identified by
MALDI-TOF mass spectrometry, 11 possess metabolic functions
(Table 2) including glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) - a known neuroprotective drug target [29–32] with a
link to PD [33] and apoptosis [34]. The prevalence of metabolic
proteins is of note, given the mechanisms (and the emergence of
genetic findings) suggesting a link between mitochondrial dysfunc-
tion and dopamine neuron loss in PD [35–39]. It is also
noteworthy that none of these proteins are involved in the
GDNF/GFRa1/RET signaling pathway.
To further demonstrate the cellular mechanism differences
between GDNF and DNSP-11, we examined DNSP-11’s protective
effects against staurosporine-induced apoptosis. Staurosporine, a
nonselective protein kinase inhibitor and cytotoxin, promotes stress-
induced apoptosis by triggering the release of cytochrome c from
mitochondria and/or the loss of mitochondria potential [40–42]. In
sympathetic and dopaminergic neurons, deprivation of GDNF was
shown previously not to initiate the release of cytochrome c into the
cytosol from the mitochondria, suggesting cell death occurs via a non-
mitochondrial pathway [43,44]. We found that DNSP-11 offers
protection from staurosporine-induced and gramicidin-induced (a
monovalent cation ionophore andmitochondria depolarization agent
[41]) cytotoxicity in dopaminergic B65 cells, unlike GDNF,
supporting that DNSP-11’s neuroprotective effects involve mito-
chondria (Figure 5C, 5D). Staining of B65 cells showed that DNSP-
11 protects against staurosporine-induced toxicity by preventing the
release of cytochrome c frommitochondria (Figure 6). Furthermore,
pull-down and ELISA analyses showed the absence of interaction
between GFRa1 with DNSP-11 (Figure S2, S3). Collectively, these
data support that DNSP-11 exhibits potent neurotrophic actions
analogous to GDNF, but likely signals through pathways that do not
directly involve the GFRa1 receptor.
Discussion
Neurotrophic factors are a class of functionally related proteins
that play a key role in neurite formation and growth during
development and after injury [45]. Because of their native cellular
function, neurotrophic factors have received considerable atten-
tion as potential therapeutic agents for neurodegenerative
disorders, including PD. Perhaps the most promising neurotrophic
factor for dopamine neurons has been GDNF. GDNF has been
shown to increase the survival of cultured dopaminergic neurons
[2], increase dopamine levels in the rat and monkey substantia
nigra, and improve motor deficits with long-lasting effects in rats
and nonhuman primate models of PD [3,4,25]. Two Phase I
clinical trials support its beneficial effects in humans, but a failed
Phase II trial and possible toxicity in an animal study have created
controversy involving CNS treatment through the use of direct
pump delivery [4–6].
Small molecules like DNSP-11 do not have the inherent
pharmacological disadvantages and challenges associated with
larger protein molecules. Furthermore, smaller peptides have the
potential, with modification, to be administered orally or nasally,
Table 2. Identified cytosolic proteins pulled-down by DNSP-
11 from substantia nigra of Fischer 344 rats.
Protein Primary Function
Aconitate Hydratase Metabolism
Alpha Enolase Metabolism
Aspartate Aminotransferase Metabolism
Creatine Kinase Metabolism
Fructose Bisphoshate Aldolase Metabolism
Glutamate Dehydrogenase Metabolism
Glutamine Synthetase Metabolism
Glyceraldehyde 3 Phosphate Dehydrogenase Metabolism/Apoptosis
L-Lactate Dehydrogenase B Chain Metabolism
Malate Dehydrogenase Metabolism
Pyruvate Kinase M1/M2 Metabolism
Heat Shock Cognate 71kDa Protein Chaperone
Actin Cytoskeleton
Tubulin Cytoskeleton
Dihydropyrimidinase-Related Protein 2 Neuronal Development
Elongation Factor-1 Alpha 2 Translation
Bound proteins were separated by 2D-PAGE (Figure S1), excised, trypsin
digested and analyzed by MALDI-TOF MS/MS. MS data were compared to the
Uniprot database [23] utilizing the ParagonTM algorithm [24] in ProteinPilot
Version 2.0 (Applied Bioscience). The proteins listed were identified by $4
peptides with .99% confidence (ProteinPilot unused score $4).
doi:10.1371/journal.pone.0009752.t002
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improving the potential for widespread use in the clinic [46–48].
DNSP-11, an 11 amino acid peptide possibly derived from the
human GDNF prosequence, is a stable, easy to synthesize and
purify molecule that opens up a new area of neurotrophic factor
development. It shares many physiological and neurotrophic
properties analogous to mature GDNF including: neuroprotection
and promoting differentiation in primary dopamine neuron cell
cultures; increasing dopamine release and metabolism in vivo; and
decreasing apomorphine-induced rotations and enhancing dopa-
mine function in the substantia nigra of 6-OHDA lesioned rats
[7,16,49]. In addition, Immonen and colleagues have shown that
the rat homolog of DNSP-11, called brain excitatory peptide
(BEP), produces an increase in synaptic excitability in rat CA1
pyramidal neurons through possible involvement of a G-protein
coupled receptor [15]. Collectively these data support that the pro-
peptides of GDNF, and perhaps other homologous neurotrophic
factor family members, such as neurturin and artemin, may have
novel, long-overlooked physiological and potentially therapeutic
functions.
Recent evidence suggests that functional peptide sequences are
present in unexpected sources. For neurotrophic proteins such as
GDNF, it is initially produced in vivo as an immature precursor
that is processed proteolytically by furin-type endopeptidases, to
liberate the mature functional protein from the propeptide [50].
While the function of the mature growth factors has been long
established, their prosequences have been thought only to be
involved in assisting protein folding and secretion [10,11].
However, the high degree of sequence conservation between
Figure 6. DNSP-11 prevents staurosporine-induced cytochrome c release from mitochondria. Confocal microscopy images demonstrate
that DNSP-11 prevents cytochrome c (green) release from mitochondria (red) of B65 cells, supporting its protection from staurosporine-induced
cytotoxicity (Figure 5C). GDNF does not prevent cytochrome c diffusion from the mitochondria when exposed to 1 mM staurosporine. The control
was citrate buffer alone. The nucleus is stained blue in all images.
doi:10.1371/journal.pone.0009752.g006
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prodomains amongst different species challenges this dogma and
strongly suggests additional biological functions [9]. Recent
evidence suggests that functional peptide sequences exist in the
prodomains of the neurotrophic factors NGF and BDNF [12–
14,50–52]. Here we have described an 11-mer peptide predicted
to be derived from proGDNF that mimics many of GDNF’s
neurotrophic actions, but is not a ligand for the GFRa1 receptor.
Additional studies are needed to investigate this potential new class
of signalling peptides, by focusing on potential metabolic/
mitochondrial mechanisms and the striatal delivery of DNSP-11
(analogous to GDNF), which may have beneficial effects in the
clinical treatment of neurodegenerative diseases such as PD.
Supporting Information
Figure S1 2D PAGE analysis of the binding partners of DNSP-
11. In the presence (top) and absence (bottom) of bDNSP-11 with
streptavidin magnetic beads. F344 substantia nigra was homog-
enized in homogenization buffer and cytosolic fraction (superna-
tant) collected after 30 minutes at 100,000 g. 50 mg of bDNSP-11
was incubated with fraction for 15 minutes on ice. Sample was
added to streptavidin magnetic beads, pelleted, and washed four
times in homogenization buffer. Bound proteins were eluted by
Solubilization/Rehydration Solution (7 M Urea, 2 M Thiourea,
50 mM DTT, 4% CHAPS, 1% NP-40, 0.2% Carrier ampholytes,
0.0002% Bromophenol blue), and analyzed by 2D-PAGE and
later identified by MALDI-TOF MS/MS (Table 1).
Found at: doi:10.1371/journal.pone.0009752.s001 (0.41 MB
DOC)
Figure S2 In vitro pull down assay determines that DNSP-11
does not bind to the GFRa1 receptor. A solution of 25 mL GFRa1
(1 mg/mL) was incubated with 50 mL of DynabeadsH (Invitrogen)
in wash and bind buffer (0.1 M sodium phosphate, pH 8.2, 0.01%
TweenH 20) for 10 minutes at room temperature. The beads were
then washed three times in 100 mL of wash and bind buffer. 2 mg
of GDNF was added and incubated for 1 hour at 4uC. 25 mL
GFRa1 (1 mg/mL) was incubated with 40 mg of biotinylated
DNSP-11 (bDNSP-11) for 1 hour at 4uC. They were then added
to 50 mL of hydrophilic streptavidin magnetic beads (New England
Biolabs) and incubated for an hour at 4uC. Expected binding was
observed between GDNF and GFRa1. However, no binding was
observed between bDNSP-11 and GFRa1. F-Flow through,
E-Elution.
Found at: doi:10.1371/journal.pone.0009752.s002 (0.07 MB
DOC)
Figure S3 Direct ELISA binding assay to verify DNSP-11 does
not interact with the GFRa1 receptor. A microtiter plate was
coated with 500 ng/ml of either GDNF or DNSP-11 in 50 mM
carbonate buffer (pH 9.6) overnight at 4uC, washed three times
with PBS plus 0.05% Tween-20 (PBST) and blocked with 2% BSA
in PBS (blocking buffer) at 37uC for 1 hour. Then, GFRa1/Fc
receptor (R&D Systems) was added at a serial dilution (range 0–
2 mg/ml) in blocking buffer. After 2 hours of incubation at room
temperature, the wells were washed three times in PBST and then
incubated with goat anti-human IgG (Fc specific) (1:10,000,
Sigma) in blocking buffer for 2 hours. Following three washes with
PBST and incubation with peroxidase-conjugated horse anti-goat
IgG (1:10,000, Vector lab) in blocking buffer for 1 hour, wells were
washed three times in PBST and two times in dH2O. The reaction
was developed with 3,39,5,59-tetramethyl benzidine (TMB)
substrate (Bio-Rad) for 10 minutes and stopped by addition of 1
N HCl. For each sample, absorbance values were recorded at 450
nm in duplicate. The wells without GFRa1/Fc receptor were used
as control. Significant binding was only observed with GDNF. No
binding above background was observed with DNSP-11.
Found at: doi:10.1371/journal.pone.0009752.s003 (0.06 MB
DOC)
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